Cyteir Therapeutics
Cambridge, US · Founded 2012 · Delaware corporation · 1 employees on LinkedIn · 3 known investors
Cyteir is a clinical-stage oncology company developing CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters. Its lead program is being studied in combination with capecitabine and gemcitabine in a Phase 1/2 clinical trial that includes patients with advanced ovarian cancer.
Founders & leadership
KM
Kevin MillsExecutive
RG
Ronald GoldsteinExecutive
DC
Donald CorcoranExecutive
MR
Markus RenschlerExecutive
Board
TR
Timothy RombergerBoard director
BM
Barry MillsBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$111.9M disclosed across 4 rounds · 2015–2021
▶$80MraisedFeb 2021 · 22 investors · BiotechnologyRule 506(b)
▶$80MraisedFeb 2021 · 22 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- TIMOTHY ROMBERGERDirector
- PAUL SECRISTExecutive Officer
- ANDREW GENGOSExecutive Officer
- SUSAN MOLINEAUXDirector
- JOSEPH S. ZAKRZEWSKIDirector
- KAREN HONGDirector
- JANWILLEM NAESENSDirector
- JEAN GEORGEDirector
- RACQUEL BRACKENDirector
- MARKUS RENSCHLERExecutive Officer, Director
- Amount sold
- $80M
- First sale
- Feb 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$20.2MraisedOct 2019 · 6 investors · BiotechnologyRule 506(b)
▶$20.2MraisedOct 2019 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- JANWILLEM NAESENSDirector
- JEAN GEORGEDirector
- RACQUEL BRACKENDirector
- MARKUS RENSCHLERExecutive Officer, Director
- KAREN HONGDirector
- TIMOTHY ROMBERGERExecutive Officer, Director
- Amount sold
- $20.2M
- First sale
- Sep 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.8MraisedMay 2018 · 12 investors · BiotechnologyRule 506(b)
▶$5.8MraisedMay 2018 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Bart Van HoolandDirector
- Timothy RombergerExecutive Officer, Director
- Ronald GoldsteinExecutive Officer
- Racquel BrackenDirector
- Markus RenschlerExecutive Officer, Director
- Jean GeorgeDirector
- Offering amount
- $35M
- Amount sold
- $5.8M
- Sales commissions
- $1.4M
- Placement agents
- MTS Securities, LLC
- First sale
- Jan 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.8MraisedNov 2016 · 15 investors · Other Health CareRule 506(b)
▶$5.8MraisedNov 2016 · 15 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Kevin MillsExecutive Officer, Director
- Barry MillsDirector
- Ronald GoldsteinExecutive Officer
- Donald CorcoranExecutive Officer, Director
- Timothy RombergerDirector
- Markus RenschlerDirector
- Offering amount
- $5.8M
- Amount sold
- $5.8M
- First sale
- Oct 2015
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlapCompanies competing with Cyteir Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Cyteir Therapeutics do?
- Cyteir is a clinical-stage oncology company developing CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters. Its lead program is being studied in combination with capecitabine and gemcitabine in a Phase 1/2 clinical trial that includes patients with advanced ovarian cancer.
- Who are Cyteir Therapeutics's investors?
- Cyteir Therapeutics's investors include Droia Ventures, Lightstone Ventures, OUP (Osage University Partners).
- How much funding has Cyteir Therapeutics raised?
- Cyteir Therapeutics has disclosed $111.9M raised across 4 rounds.
- Where is Cyteir Therapeutics headquartered?
- Cyteir Therapeutics is headquartered in Cambridge, US.